Session Summary: Alzheimer’s Disease presents a growing public health and caregiving challenge. Acetylcholinesterase inhibitors (AChEIs)—donepezil,rivastigmine, and galantamine/benzgalantamine—remain the cornerstone of pharmacologic treatment, aiming to preserve cognition, slow functional decline, mitigate behavioral symptoms, and reduce caregiver burden. Despite decades of use, knowledge gaps have emerged about their efficacy and side effects: This session reexamines the clinical role of AChEIs—the current evidence, pharmacologic nuances, and real-world outcomes to guide optimal, evidence-based application in today’s care settings.
Learning Objectives:
At the completion of this session, learners will be able to:
Describe the unique challenges and care needs of individuals living with Alzheimer’sDisease in long-term care settings.
Evaluate current clinical evidence of the safety, efficacy, tolerability, and outcomes associated with acetylcholinesterase inhibitors (AChEIs) use, for patients with Alzheimer’s Disease.
Identify interdisciplinary strategies to overcome barriers to AChEI use including side effect management, caregiver engagement, and improving medication adherence and continuity in long-term care environments.
